{"disease":{"id":"anti-pd-1-antibody-resistant","name":"anti pd 1 antibody resistant"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04514081","title":"The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}